AI-ECG Platform
Contact for pricing
Regulatory Status Disclosed
Overview
The AI-ECG Platform by Shenzhen Carewell Electronics Co., Ltd. (a subsidiary of Lepu Medical) is an artificial intelligence-powered analysis and interpretation system designed to assist healthcare professionals in evaluating resting electrocardiograms (ECGs). The platform acts as an advisory tool, allowing clinicians to review, confirm, edit, or delete automatically generated interpretations.
Target Specialties and Care Settings:
- Specialties: Cardiology, primary care, emergency medicine, and general practice.
- Care Settings: Hospitals, private clinics, community health centers, physical examination centers, and ambulatory care facilities.
Workflow Integration:
- Data Import: The platform is hardware-independent and compatible with resting ECG devices that export standard formats, including Carewell ECG, HL7 aECG, DICOM ECG, SCP ECG, and MFER ECG. Data can be transmitted via LAN, USB, or other supported protocols.
- Analysis and Review: The system features a dedicated diagnostic client for waveform measurement, heartbeat annotation, and ECG review.
- Reporting and Connectivity: Clinicians can generate customized diagnostic reports and connect the software directly with Hospital Information Systems (HIS).
Notable Capabilities:
- Supports the measurement and interpretation of up to 12-channel resting ECGs.
- Assists in the assessment of common cardiac abnormalities, including arrhythmias, myocardial infarction, ventricular hypertrophy, and abnormal ST-T changes.
- Features a web-based management portal to coordinate daily ECG test tasks, manage organization settings, and compile work statistics.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-powered automatic ECG analysis and diagnosis
- Over 95% accuracy in diagnosing major cardiovascular diseases
- Diagnoses arrhythmias, ventricular hypertrophy, myocardial ischemia, and myocardial infarction
- Hardware independent, compatible with most ECG machines
- Web-based Management Portal for organization settings, security, and task management
- AI-ECG Diagnostic Client for professional ECG review, waveform measurement, and report generation
- Rapid diagnosis in approximately 3 seconds
- Supports various ECG data formats: Carewell ECG, HL7 aECG, DICOM ECG, SCP ECG, MFER ECG
- Trained with over 47 million ECG data and deep learning algorithms
- Real-time ECG monitoring and warning for up to 45 abnormal ECG events
Use Cases
- Localized and rapid ECG analysis in primary hospitals, private clinics, medical examination centers, and community health centers
- Reducing workload and improving efficiency for professional ECG physicians in large hospitals
- Enabling home ECG monitoring for patients
- Improving ECG analysis and diagnosis for wearable devices to a professional level
What Physicians Need to Know
ECG/EKG Analysis Capability
The AI-ECG Platform is an AI-powered analysis system designed to assist physicians in measuring and interpreting 12-lead resting ECGs. It provides fast AI computing support for accurate and rapid ECG waveform recognition, processing, analysis, interpretation, and diagnosis. The system can detect over 100 ECG abnormalities, including arrhythmias, ventricular hypertrophy, myocardial ischemia, and myocardial infarction. It offers features such as ECG review, waveform measurement, heartbeat annotation, interpretation, electrical signature, and report generation.
Arrhythmia Detection Accuracy
The platform boasts high accuracy in diagnosing arrhythmias and other cardiac abnormalities, with an overall accuracy of 95% for conditions like arrhythmias, ventricular hypertrophy, myocardial ischemia, and myocardial infarction. Its AI neural network system achieves an accuracy of 98.3% in automatic data analysis. It can detect more than 100 ECG abnormalities with up to 98% accuracy.
Heart Failure Related Diagnostics
While not explicitly a 'heart failure risk prediction' tool, the platform accurately diagnoses conditions such as ventricular hypertrophy and myocardial infarction, which are significant indicators and causes of heart failure. The AI analyzes ECG data to identify these common cardiac abnormalities.
Coronary Artery Related Diagnostics
The AI-ECG Platform is capable of diagnosing myocardial ischemia and myocardial infarction, which are directly related to coronary artery disease. It assists in the assessment of these critical cardiac abnormalities through ECG interpretation.
Cardiac Monitoring Integration
The AI-ECG Platform is hardware independent and compatible with various resting ECG devices that can export recordings in formats such as Carewell ECG, HL7 aECG, DICOM ECG, SCP ECG, and MFER ECG. It can also be integrated with devices like the 'CHECKME' AI-powered health monitor for ECG recording. The CAREWELL AI-ECG mobile application supports data collection from wearable devices via Bluetooth.
Physician Tip
The AI-ECG Platform serves as a powerful advisory tool, significantly enhancing the efficiency and accuracy of ECG interpretation. Physicians should confirm, edit, or delete interpretations provided by the AI, integrating these insights with their clinical knowledge and patient history for a comprehensive diagnosis. Leverage its rapid analysis capabilities to streamline workflow and focus on complex cases. The platform's hardware independence allows for seamless integration into existing clinical setups, minimizing capital expenditure.
The AI-ECG Platform is designed for broad compatibility, supporting various standard ECG data formats including Carewell ECG, HL7 aECG, DICOM ECG, SCP ECG, and MFER ECG. Its hardware-independent nature means it can be utilized with almost all existing ECG machines, offering flexibility and cost-effectiveness for healthcare facilities. The system also supports data acquisition from wearable devices via a mobile application.
Details
| Category | Cardiology AI |
| Pricing | Contact for pricing |
| Deployment | Workstation (with GPU), web-based portal, Windows-based diagnostic client |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
1 AI-estimated The AI-ECG Platform received FDA clearance (K180432) on November 19, 2018. It is an artificial intelligence (AI) automatic analysis and diagnosis system for ECG, intended to assist physicians in measuring and interpreting 12-lead resting ECGs. |
| Integrations | |
| EHR | Not specified |
| Specialties | Cardiology, Emergency Medicine, Internal Medicine |
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate AI-ECG Platform
Press & Coverage
Carewell Health
AI-ECG Platform Gets FDA Clearance
On November 19, 2018, Shenzhen Carewell Electronics Co., Ltd., a subsidiary of Lepu Medical, announced that its AI-ECG Platform received FDA clearance, marking it as the first Chinese innovative medical device in the AI ECG field with this approval.
2018-11
Carewell Health
Artificial Intelligence Fuels ECG u2013Lepu Medical Launched AI-ECG Platform System
On March 24, 2018, Lepu Medical launched its in-house AI-ECG Platform, an automatic ECG analysis & diagnosis system, at the 16th China Interventional Therapeutics (CIT), signifying Lepu's move towards comprehensive AI development in healthcare.
2018-03
Synced Review
AI-Powered & FDA-Approved Medical Health Projects
In February 2019, Synced Review reported that Carewell, a subsidiary of Lepu Medical, received FDA approval for its AI-ECG Platform in November of the previous year. This diagnostic program covers major cardiovascular diseases and can detect various cardiac abnormalities.
2019-02
BMJ Health & Care Informatics
How machine learning is embedded to support clinician decision making: an analysis of FDA-approved medical devices
A 2021 article in BMJ Health & Care Informatics references the AI-ECG Platform (K180432) from Shenzhen Carewell Electronics, Ltd., as an FDA-approved medical device utilizing machine learning for ECG analysis support.
2021-04
ResearchGate (npj Digital Medicine)
The state of artificial intelligence-based FDA-approved medical devices and algorithms: an online database
A September 2020 article on ResearchGate, originally from npj Digital Medicine, lists the AI-ECG Platform by Shenzhen Carewell Electronics., Ltd. as an FDA-approved device for ECG analysis support (K180432) in the cardiology field from 2018.
2020-09
World Journal of Current Medical and Pharmaceutical Research
Software programmes employed as medical devices
A June 2023 article discusses the AI-ECG Platform as an example of AI-infused software in medical devices, highlighting its use in hospitals and healthcare institutions for detecting common cardiac problems.
2023-06
JAMA Network (PMC)
Analysis of Devices Authorized by the FDA for Clinical Decision Support in Critical Care
An October 2023 analysis of FDA-authorized devices for clinical decision support in critical care lists the AI-ECG Platform by Shenzhen Carewell Electronics, Ltd., authorized on November 19, 2018, via the 510(k) Premarket notification pathway for measuring and interpreting ECG.
2023-10
MDPI
Artificial Intelligence in Translational Medicine
A November 2021 publication mentions the AI-ECG Platform (Shenzhen Carewell Electronics, Ltd.) as an AI platform for assisting physicians in measuring and interpreting ECG, with FDA clearance (K180432) in Cardiology in November 2018.
2021-11
Videos
Product demos, reviews, and walkthroughs for AI-ECG Platform.
No videos found. Search YouTube directly
Frequently Asked Questions
AI-ECG platforms are designed for seamless integration into existing clinical workflows, often connecting with Electronic Health Records (EHRs) and current ECG devices. Many solutions offer web and desktop applications, allowing physicians to access and interpret AI-powered analyses efficiently within their established systems.
These platforms can detect a broad spectrum of ECG abnormalities, including various arrhythmias like atrial fibrillation, sinus tachycardia, and paced rhythms, as well as critical conditions such as STEMI and left ventricular systolic dysfunction. Some advanced AI-ECG models can also identify subtle indicators of conditions like hypertrophic cardiomyopathy, pulmonary hypertension, and other structural heart diseases.
Many AI-ECG platforms have received regulatory clearances, such as FDA clearance in the U.S. or CE marking in the European Union, with some even earning FDA Breakthrough Device Designation. It is crucial for physicians to verify the specific regulatory status of any AI-ECG platform they intend to use, as availability and approved indications can vary by region.
Reputable AI-ECG platforms prioritize data privacy and security, adhering to regulations like HIPAA and GDPR. They typically implement robust measures such as data de-identification, encryption, and secure system architectures, often requiring Business Associate Agreements (BAAs) to ensure the confidential handling of Protected Health Information (PHI).
AI-ECG platforms have demonstrated diagnostic performance comparable to, and in some studies even superior to, conventional physician interpretation for specific cardiac conditions, often with higher sensitivity and specificity and reduced time to diagnosis. However, these tools are generally intended to augment, rather than replace, human expertise, providing a secondary analysis to support clinical decision-making.
While specific pricing models vary by vendor, the Centers for Medicare & Medicaid Services (CMS) has established national payment rates for AI-powered ECG analysis, indicating a growing pathway for reimbursement in the U.S. Studies suggest that AI-ECG algorithms can be a cost-effective screening tool, particularly in outpatient settings, by facilitating earlier diagnosis and potentially leading to overall healthcare cost savings.
AI-ECG platforms have inherent limitations, including the potential for false positives and negatives, especially when detecting rare conditions or if used without appropriate clinical context. These platforms are designed as assistive tools to enhance diagnostic accuracy and efficiency, but they cannot entirely replace the nuanced judgment and comprehensive clinical assessment provided by a human physician.
Compare AI-ECG Platform
VS
AI-ECG Platform vs Sleepiz One+
The AI-ECG Platform is designed for in-depth, AI-powered analysis and diagnosis of 12-lead resting ECGs, focusing on specific cardiovascular diseases. In contrast, Sleepiz One+ offers contactless remote patient…
VS
AI-ECG Platform vs PMcardio
Both tools offer AI-powered ECG analysis for diagnosing various cardiac conditions, making them direct competitors in the cardiology AI space. While Tool A emphasizes high accuracy in diagnosing…
VS
AI-ECG Platform vs EchoNext
Both the AI-ECG Platform and EchoNext are FDA-cleared AI tools that analyze standard ECGs to assist in cardiac diagnosis. While the AI-ECG Platform focuses on comprehensive analysis of…
VS
AI-ECG Platform vs Cardiomo
These tools are adjacent in their focus on AI-powered cardiovascular disease detection but serve different primary use cases. Tool A, the AI-ECG Platform, is designed for clinical settings,…
Suggest an Edit →
| Last Verified: 2026-04-19 | First Added: 2026-04-19